Claim construction issues in ANDA case

Posted on April 4, 2011 by Morris James LLP

Mylan Pharmaceuticals Inc. v. Galderma Laboratories, Inc., et al., Civ. No. 10-892-LPS, March 24, 2011.

Stark, J.  The court construes disputed terms in ANDA dispute involving generic version of Oracea.

The disputed technology relates to the use of antibiotics, such as doxycycline, to treat inflammatory shin conditions, including rosacea.  The court construes 2 terms on the patent-in-suit.  The complaint was filed on October 18, 2010.  Briefing on claim construction was completed on March 13, 2011 and a Markman hearing was held on March 21, 2011.
Tags: ,
Trackbacks (0) Links to blogs that reference this article Trackback URL
http://depatentlaw.morrisjames.com/admin/trackback/244644
Comments (0) Read through and enter the discussion with the form at the end
Post A Comment / Question Use this form to add a comment to this entry.







Remember personal info?
Send To A Friend Use this form to send this entry to a friend via email.